Richtlinien zu Diagnostik und Therapie von Erkrankungen sollten \u201dEvidenz-basiert\u201d sein. Da\u00df man Evidenz unterschiedlich bewerten oder klinische Studien f\u00fcr mehr oder weniger mangelhaft halten kann, zeigt ein Vergleich der neuen therapeutischen Richtlinien f\u00fcr den Diabetes mellitus Typ 2 (DM2). Erstens gibt es die Nationale Versorgungs-Leitlinie (NL), die von der Bundes\u00e4rztekammer, der Arzneimittelkommission der deutschen \u00c4rzteschaft […]<\/p>\n","protected":false},"excerpt":{"rendered":"
Richtlinien zu Diagnostik und Therapie von Erkrankungen sollten \u201dEvidenz-basiert\u201d sein. Da\u00df man Evidenz unterschiedlich bewerten oder klinische Studien f\u00fcr mehr oder weniger mangelhaft halten kann, zeigt ein Vergleich der neuen therapeutischen Richtlinien f\u00fcr den Diabetes mellitus Typ 2 (DM2). Erstens gibt es die Nationale Versorgungs-Leitlinie (NL), die von der Bundes\u00e4rztekammer, der Arzneimittelkommission der deutschen \u00c4rzteschaft […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1146,130,525,316,309,312,314,313,315,438,527,317,320,311,307,319,310,129,128,131,324,155,1871,1626,1872,323,638,413,1731,156,663,325,50,1875,1730,1876,1874,157,1332,1866,1867,306,476,1868,1869,1870,1864,1863,1865],"class_list":["post-1003","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acarbose","tag-ace-hemmer","tag-akdae","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-antihypertensiva","tag-arzneimittelkommission-der-deutschen-aerzteschaft","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-blutdruck","tag-diabetes-mellitus-typ-2","tag-diabetes-diaet","tag-diabetische-nephropathie","tag-disease-management-programm","tag-ernaehrung","tag-glibenclamid","tag-glimepirid","tag-glipizid","tag-glitazone","tag-glyburid","tag-hypertonie","tag-insulin","tag-koordinierungsausschuss","tag-metformin","tag-nateglinid","tag-nationale-versorgungs-leitlinie","tag-orale-antidiabetika","tag-pioglitazon","tag-repaglinid","tag-rosiglitazon","tag-sartane","tag-sulfonylharnstoffe","tag-ukpds-studie-24","tag-ukpds-studie-33","tag-ukpds-studie-34","tag-ukpds-studie-38","tag-ukpds-studie-39","tag-ukpds-studie-40"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1003"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1003\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}